Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Mar 8, 2022 · 10-K · 67 days after period end · 0001564590-22-008995
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $3.64M | — | $0.00 | $0.00 |
| Net Income | -$20.45M | -$22.71M | -$21.50M | -$14.90M |
| EPS Diluted | — | -$0.35 | -$0.65 | -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 8, 2022 · 67 d after period end
